Endorectal T2-weighted MRI does not differentiate between favorable and adverse pathologic features in men with prostate cancer who would qualify for active surveillance

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 3, 2012, Pages 301-305

  Guzzo, Thomas J ^a   Resnick, Matthew J ^a   Canter, Daniel J ^a   Bivalacqua, Trinity J ^b   Rosen, Mark A ^a   Bergey, Meredith R ^a   Magerfleisch, Laurie ^a   Tomazewski, John E ^a   Wein, Alan J ^a   Malkowicz, S Bruce ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Active surveillance; Endorectal MRI; Prostate cancer; Staging

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER INVASION; CANCER PATIENT; CANCER SIZE; CANCER STAGING; COHORT ANALYSIS; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY;

AGED; COHORT STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECTUM; RETROSPECTIVE STUDIES;

EID: 84860283973     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.08.023     Document Type: Article

References (16)

1. Lilja H., Ulmert D., Vickers A.J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008, 8:268-278.
2. Penson D.F., Rossignol M., Sartor A.O., et al. Prostate cancer: Epidemiology and health-related quality of life. Urology 2008, 72:S3-S11.
3. Draisma G., Boer R., Otto S.J., et al. Lead times and overdetection due to prostate specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003, 95:868-878.
4. Sakr W.A., Grignon D.J. Prostate cancer: Indicators of aggressiveness. Eur Urol 1997, 32:15-23.
5. Han M., Partin A.W., Pound C.R., et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001, 28:555-565.
6. Lagerveld B.W., Laguna M.P., de la Rosette J.J. Long-term results after external beam radiation therapy for T1-T2 localized prostate cancer. Curr Urol Rep 2003, 4:240-247.
7. Klein E.A., Ciezki J., Kupelian P.A., et al. Outcomes for intermediate risk prostate cancer: Are there advantages for surgery, external radiation, or brachytherapy?. Urol Oncol 2009, 27:67-71.
8. D'Amico A.V., Schnall M., Whittington R., et al. Endorectal coil magnetic resonance imaging identifies locally advanced prostate cancer in select patients with clinically localized disease. Urology 1998, 51:449-454.
9. Kirkham A.P., Emberton M., Allen C. How good is MRI at detecting and characterizing cancer within the prostate?. Eur Urol 2006, 50:1163-1174.
10. Carter H.B., Kettermann A., Warlick C., et al. Expectant management of prostate cancer with curative intent: An update of the Johns Hopkins Experience. J Urol 2007, 178:2359-2365.
11. Guzzo T.J., Vira M.A., Neway H., et al. Minimal tumor volume may provide additional prognostic information in good performance patients after radical prostatectomy. Urology 2007, 69:1147-1151.
12. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
13. Barocas D.A., Cowan J.E., Smith J.A., et al. CaPUSURE Investigators: What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance?. An analysis of the CaPSURE database. J Urol 2008, 180:1330-1334.
14. Warlick C., Trock B.J., Landis P., et al. Pathologic outcomes are similar for men in an expectant management program undergoing delayed surgical intervention compared with those undergoing immediate intervention. J Natl Cancer Inst 2006, 98:355-357.
15. Cabrera A.R., Coakley F.B., Westphalen A.C., et al. Prostate cancer: Is inapparent tumor at endorectal MR and MR spectroscopic imaging a favorable prognostic finding in patients who select active surveillance?. Radiology 2008, 247:444-450.
16. Shukla-Dave A., Hricak H., Kattan M.W., et al. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int 2007, 99:786-793.